<DOC>
	<DOCNO>NCT01518621</DOCNO>
	<brief_summary>To determine erlotinib give orally along concurrent whole brain irradiation lung cancer patient brain metastases improve median overall survival enhance local control compare treated WBRT alone , without significantly increase risk side effect lower quality life .</brief_summary>
	<brief_title>Whole Brain Radiation With Without Erlotinib Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Endpoints Primary : â€¢ To determine erlotinib give orally along concurrent WBRT lung cancer patient brain metastasis , improve median overall survival compare treated WBRT alone . Secondary : - To confirm safety profile erlotinib along concurrent WBRT , context treat central nervous system malignancy . - To evaluate erlotinib along concurrent WBRT increase local control rate measure MRI 8 week , compare WBRT alone . - To evaluate erlotinib along concurrent WBRT increase time neurologic progression disease base neuropsychological assessment baseline , 8 20 week WBRT . - To evaluate quality life parameter patient treat WBRT alone vs concomitant erlotinib WBRT - To evaluate mutation status impact mention parameter Trial design Open multicenter randomize phase II trial . Patients Patients &gt; 18 year histologically confirm NSCLC brain metastasis verify either CT MRI , eligible neurosurgery stereotactic radiation therapy . Trial treatment Patients randomize 1:1 either treatment arm A B . - Arm A : WBRT 3 Gy x10 alone . - Arm B : WBRT 3 Gy x10 erlotinib give concomitantly , 150 mg p.o . daily day radiation , last day radiation . Number patient 150 patient include , 75 arm</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm advanced nonsmall cell lung cancer ( NSCLC ) meet 1 follow criterion : Newly diagnose multiple brain metastasis suitable firstline chemotherapy Relapsed NSCLC newly diagnose multiple brain metastasis Relapsed NSCLC secondline chemotherapy regimens newly diagnose multiple brain metastasis Diagnosis brain metastasis confirm MRI ( CT MRI available/possible ) within past 4 week Symptoms attributable brain metastasis Patients undergone craniotomy incomplete resection eligible Clinician 's opinion wholebrain radiotherapy ( WBRT ) beneficial ECOG PS 02 Age 18 year Serum bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN ( &lt; 5 time ULN liver metastasis present ) Creatinine &lt; 1.5 time ULN Able take oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior concurrent malignant disease likely interfere study treatment comparison More 3 site ( organ system ) extracranial metastasis Evidence solitary brain metastasis MRI treat surgical resection , radiosurgery , stereotactic radiotherapy Evidence significant laboratory find concurrent uncontrolled medical illness , opinion investigator , would interfere study treatment result comparison render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>